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Endometriosis is a common and painful condition affecting women of reproductive age. While the underlying
pathophysiology is still largely unknown, much advancement has been made in understanding the progression of
the disease. In recent years, a great deal of research has focused on non-invasive diagnostic tools, such as biomarkers, as
well as identification of potential therapeutic targets. In this article, we will review the etiology and cellular mechanisms
associated with endometriosis as well as the current diagnostic tools and therapies. We will then discuss the more recent
genomic and proteomic studies and how these data may guide development of novel diagnostics and therapeutics.
The current diagnostic tools are invasive and current therapies primarily treat the symptoms of endometriosis. Optimally,
the advancement of “-omic” data will facilitate the development of non-invasive diagnostic biomarkers as well as
therapeutics that target the pathophysiology of the disease and halt, or even reverse, progression. However, the amount
of data generated by these types of studies is vast and bioinformatics analysis, such as we present here, will be critical to
identification of appropriate targets for further study.
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Endometriosis is considered to be a benign gynecological
condition. However, it is extremely common, affecting
up to 10% of women of reproductive age and can present
with severe symptoms such as chronic pelvic pain, pain
with menstruation, pain during intercourse (dyspareunia),
and dysmenorrhea [1]. While the underlying pathophysi-
ology of endometriosis remains elusive, it is known to be
a hormone-dependent disease characterized by ectopic
endometriotic lesions. In fact, the pain associated with the
severe deep-infiltrating form of the disease is frequently
due to the penetration of the muscularis propria by endo-
metriotic lesions in the peritoneal cavity, fallopian tubes,
rectosigmoid colon, and bladder [2]. Furthermore, endo-
metriotic lesions can result in scarring of the reproductive
organs causing infertility in up to 30% of women who
suffer from endometriosis [3,4]. There are many theories* Correspondence: yanaaznaurova@gmail.com
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analysis of the involved signaling pathways will lay a critical
foundation for the development new therapies.Epidemiology: the rise of endometriosis
The exact prevalence of endometriosis in the population
today is difficult to determine because it is asymptomatic
or subclinical in the majority of cases. The prevalence
has been estimated to be as low as 1% among asymp-
tomatic women and as high as 60% in women with
chronic pelvic pain [5,6].
A 2012 study of a German insurance cohort found
that the overall prevalence was approximately 0.8% [5].
However, this particular study was enriched for asymp-
tomatic patients in that four age matched controls were
identified for each symptomatic patient. This is contrary
to the vast majority of studies which are enriched for
symptomatic patients, such as a 2013 study in which
62% of adolescent girls being followed for either chronic
pelvic pain or dysmenorrhea were diagnosed with endo-
metriosis [6]. Such disparate reports emphasize the com-
plexity of determining, with any certainty, either the
prevalence or incidence of this disease.tral Ltd. This is an Open Access article distributed under the terms of the
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that the prevalence of endometriosis may actually be
lower than was previously thought, there has been a
perceived increase in the incidence of endometriosis in
the past several decades [5,7]. This perception may be




As a hormone-dependent disease of continued endomet-
rial growth, endometriosis is predominantly a disease
of women of reproductive age. Endometriosis is rarely
found in pre-adolescents with an incidence of only
0.05% in symptomatic patients. In women of reproduct-
ive age, the highest incidence was found in women aged
35–44 (0.4%) (relative risk (RR) = 6.3), regardless of
symptoms [5]. This is in comparison to women aged
25–34 (RR – 4.0) and 45–54 (RR - 4.5), respectively [5].
However, endometriosis is also frequently diagnosed in
symptomatic post-menopausal women (incidence of
2.55%) [8]. It is possible that an increase in endometri-
osis can be attributed, in part, to the aging of the global
population.
Lifestyle
 Reduced pregnancy rate
The theory that drastically decreased pregnancy rates
as a direct result of the modern woman’s lifestyle, in-
cluding the availability of contraceptives, contributes to
an increased incidence of endometriosis is well established
[9-11]. In the absence of frequent pregnancy, the endomet-
rium continually builds-up and then sheds under the
control of hormonal signaling. It is thought that the
cycling of the endometrium with more frequent men-
ses can lead to endometriosis. Evidence that symp-
toms of endometriosis resolve during pregnancy has led
to frequent treatment with the use of oral contraceptive
pills (OCPs) to induce “pseudopregnancy” [12,13]. Even
though most women still experience monthly menses
while taking OCPs, the hormonal levels simulate
pregnancy thereby inhibiting ovulation but also decreasing
endometrial build-up and menstrual flow as well as impro-
ving endometriosis symptoms.
 Shift work
Menstrual cycle and endometriosis are both driven by
circulating estrogen levels [14]. There is evidence to sug-
gest that estrogen levels in women of reproductive age
follow a circadian rhythm in addition to the monthly
ovarian rhythm and, therefore, may be vulnerable tocircadian disturbance [15,16]. In fact, night shift work
has been shown to affect estrogen secretion and has
been associated with menstrual disruption as well as in-
creased risk of endometriosis [17,18]. One study found
that any night shift work at all increased the risk of
endometriosis by 50% [14].
Toxins
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and struc-
turally related polyhalogenated aromatic hydrocarbon
chemicals (PHAHs) are common environmental con-
taminants found globally. TCDD and dioxin-like PHAHs
are classified as “dioxins” and are associated with a
spectrum of toxic effects on the reproductive, immune,
and endocrine systems [19]. Additionally, polychlorinated
biphenyls (PCBs) contribute to the toxicity of PHAHs in-
cluding disruption of estrogen activity [20,21].
Dioxins are released into the air as a product of vari-
ous industrial processes and, therefore, exposure has
steadily increased over the last century [22]. The com-
pounds accumulate in the environment and people are
exposed through the consumption of animal products as
the compounds bioaccumulate in fatty tissues [23]. Food
sources account for 93% of dioxin exposure levels in the
US population, although inhalation, soil, and water sources
may also play a role [24].
A clear relationship between dioxin exposure and the
development of endometriosis has been well established
in both rodent and primate models [25-29]. However, a
causal relationship between the two has not yet been
verified in humans though there is evidence to support
it. For example, development of ectopic lesions is in-
duced by dioxin exposure in a rodent model using
human endometrium [30,31]. Moreover, studies from
around the globe have linked an increased risk of endo-
metriosis with elevated concentrations of dioxin in pa-
tient serum [32-35].
Autoimmunity
Endometriosis is understood to be an inflammatory dis-
ease process, which suggests a role for the immune sys-
tem [36]. It has been postulated that one mechanism for
the development of ectopic endometrial lesions is a
defective immune response, which fails to clear the im-
plants from the peritoneal surface [36,37]. In fact, im-
mune deficits fulfilling most of the basic criteria for
autoimmune disease have been described in endomet-
riosis, including polyclonal B-cell activation, abnor-
malities in T- and B-cell function, tissue damage, and
multi-organ involvement [38,39]. Furthermore, aller-
gies, hypothyroidism, inflammatory bowel disease, and
fibromyalgia are among a number of autoimmune condi-
tions known to be associated with endometriosis [40,41].
However; it remains unclear whether these comorbidities
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most convincing evidence that endometriosis may have an
autoimmune component is the presence of circulating
antibodies towards ovarian and endometrial antigens
[42-45]. These auto-antibodies are likely to play a role in
both the pathogenesis of endometriosis as well as preg-
nancy loss in patients with the disease, but further study is
needed to firmly establish these links [43,44].
Etiology
Retrograde menstruation theory
Approximately 75-90% of women experience some retro-
grade intra-abdominal bleeding during menses [46]. The
development of endometriosis has been linked to exposure
of the pelvic peritoneum to the blood products and cellular
debris contained within menstrual fluids, which would nor-
mally be confined to the pelvis [46,47]. Furthermore, men-
strual fluid also contains some abnormal stem cells, which
have been shown to have increased implantation and an-
giogenic capabilities and can form ectopic tissue lesions in
animal models [47,48].
Coelomic metaplasia
While retrograde menstruation is the most widely ac-
cepted mechanism, it cannot explain rare cases of endo-
metriosis in the absence of a functioning uterus. The
coelomic metaplasia theory proposes that endometriosis
develops as a result of transformation of mesothelial
cells on the ovary to endometriotic gland cells [49,50].
In fact, mesothelial inclusions have been found to be
associated with endometriosis in the ovaries, fallopian
tube, and pelvic wall [51]. Rare cases of endometriosis
described among men, pubertal and adolescent girls, and
distant endometriosis in the thoracic cavity support this
particular theory [52-54]. Furthermore, an in vitro experi-
mental model of human endometriosis demonstrated that
ectopic lesions can result from metaplasia of the ovarian
surface epithelium [55].
Lymphovascular metastasis
The theory of lymphatic and hematogenous spread has
long been considered to explain remote occurrence of
the disease as well. According to this theory, exfoliated
endometrial cells are swept into the venous drainage of
the uterus, with subsequent deposition possible any-
where in the body. The theory is supported by the pres-
ence of endometriosis in the thoracic cavity and other
distant sites outside pelvis as well as detection of endo-
metrial tissue in the uterine vessels in patients with ade-
nomyosis [56]. Lymphovascular metastasis remains a
speculative explanation and, while possibly occurring
during the development of endometriosis, is not likely to
be the primary mechanism as cases of pulmonary and
thoracic endometriosis are rare [57,58].Embryonic rest theory
During embryogenesis, some endometrial cells that
should grow in the uterus develop in the abdomen
instead [59]. These cells would then be activated in
puberty under the effects of estrogen and progesterone.
Embryogenesis is controlled and directed by a sophisti-
cated, but still incompletely understood, fetal system.
This fetal developmental control system may be the fetal
analog of the adult immune system. Abnormalities of the
fetal development control system may be preserved into
adult life, giving rise to detectable abnormalities of the
adult immune system [60,61]. The degree of residual ab-
normality of the adult immune system may control the
aggressiveness of the endometriosis that develops, with
the result that some patients may develop invasive dis-
ease or adhesions, while most do not.
Smooth muscle cells
Endometrial stromal cells (ESCs) are the most prevalent
cell type in endometriotic lesions. However, smooth
muscle cells (SMCs) are also frequently found and have
been reported in peritoneal, ovarian, and deep-infiltrating
endometriosis [62-65]. Peritoneal SMCs express oxytocin
receptors (OTRs), estrogen receptors (ERs), and progester-
one receptors (PRs), which are required components of
uterine myometrial cells [66]. In contrast, the ability of
SMCs to produce contractions has not been demonstrated.
It is plausible that peritoneal SM contractions could stimu-
late peritoneal nociceptors leading to the generation of
endometriosis-associated pain [67]. However, whether
these SMCs are derived from basal stem cells or reacti-
vated coelomic epithelial cells is still unclear [68].
Altered immune response
Macrophages are an integral component of the mono-
nuclear phagocyte system (MPS). They are derived from
bone marrow progenitors that enter the circulation as
monocytes. After reaching peripheral tissues, they reside
as macrophages or antigen-presenting cells, including
dendritic cells (DCs). The MPS performs both pathogen
eliminating and homeostasis support functions [69,70].
In mouse models, in the absence of macrophages, endo-
metriotic tissue retains the ability to adhere to the peri-
toneal layer [71]. However, the angiogenic properties
were inhibited and endometriotic lesions failed to grow.
Infiltrating macrophages have been reported as a con-
sistent feature of endometriotic lesion development in
humans. Independent studies have indicated that they
are activated by sequence of signals generated within ec-
topic endometrial lesions or because of the lack of anti-
inflammatory hormone-regulated signals in ectopic sites
[72-76]. Macrophages are also known to be the source
of several chemokines that are involved in endometri-
osis [71]. However distinct molecular mechanisms that
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be defined.
Cellular mechanisms
Endometriosis has long been understood to be a disease
of uncontrolled and aberrant growth of endometrial tis-
sue. However, the cellular and molecular mechanisms
that are disrupted in this disease remain ill defined. The
cell signaling pathways involved can be divided into
those involved in proliferation and apoptosis, adhesion
and invasion, angiogenesis, and immune function.
Proliferation and apoptosis
The mechanisms regulating endometrial cell prolifera-
tion are primarily controlled by interactions between the
sex steroids and their receptors [77]. Cyclical regulation
of cellular proliferation by sex hormones is lost in endo-
metriotic tissue. It is well-known, that alterations in cell
cycle molecules such as cyclin and cyclin-dependent
kinases are hormone dependent [78]. For example,
FOXO1A, a transcription factor involved in cell cycle con-
trol and apoptosis, is regulated by progesterone and its ex-
pression is significantly reduced in the endometrial tissue
of women with endometriosis. Another cell cycle regula-
tory protein, ErbB-2 (TOB1) is also known to be down-
regulated in women with endometriosis, which may be the
result of increased interleukin (IL)-1β levels.
Growth factors also contribute to the increased prolif-
erative potential of cells derived from endometriotic
lesions. In fact, epidermal growth factor (EGF) is con-
firmed to stimulate proliferative activity in these cells
[79,80]. Mitogen inducible gene 6 (MIG6) is a negative
regulator of EGF signaling. MIG6 is down-regulated in
women with endometriosis and may, therefore, contrib-
ute to unmitigated growth of endometrial cells. Midkine
(MK) is a member of the heparin-binding growth factor
family that is over-expressed in the ectopic endomet-
rium, which has been implicated in proliferation, migra-
tion, angiogenesis, and fibrinolysis [81] [Figure 1].
The recurrent bleeding that is a hallmark feature of
endometriosis leads to continual thrombin generation,
which can subsequently stimulate proliferation of endo-
metriotic cells via protease-activated receptor 1 (PAR1)
[77]. PAR1 downstream signaling induces expression
of monocyte chemoattractant protein-1 (MCP1), tis-
sue necrosis factor alpha (TNFα), interleukins (IL),
cyclooxygenase-2 (COX-2), matrix metalloproteinases
(MMP), hepatocyte growth factor (HGF), and tissue fac-
tor (TF) [77]. Inhibition of COX-2 effectively reduces
endometriotic epithelial cell proliferation [82]. Further-
more, TNFα, various interleukins, and HGF, which are
known to be significantly elevated in the peritoneal fluid
of women with endometriosis, also contribute to prolifer-
ation of endometriotic cells [83,84].Leptin is primarily known as the protein released by
fat cells. However, leptin is also found at elevated levels
in the peritoneal fluid and serum of patients with endo-
metriosis [85]. Leptin expression can be stimulated by
pro-inflammatory cytokines such as TNFα and IL-1 and
can, in turn, stimulate proliferation of ectopic endome-
triotic cells [77,85]. Retinoic acid (Vitamin A), on the
other hand, is known to protect against endometriosis [86].
However, the retinoic acid catabolic enzyme CYP26A1, is
a progesterone responsive gene that is upregulated in
women with endometriosis [87]. By inactivating retinoic
acid, CYP26A1 contributes to establishment of endome-
triotic lesions.
The Aryl Hydrocarbon Receptor (AHR) transcription
factor is recognized as the culprit for most toxic re-
sponses observed after exposure to PAH (Polycyclic aro-
matic hydrocarbons), dioxins, and PCBs. AHR can affect
cellular signaling through interactions with various regu-
latory and signaling proteins, including those mediated
by the estrogen receptor (ESR) and NF-κB (nuclear fac-
tor of kappa light polypeptide gene enhancer in B cells)
[88]. AHR activation leads to decreases in both the num-
ber of ESRs and ESR responsiveness, as well as in-
creases in ESR metabolism. Activated AHR complexes
associate directly with ESR-α and -β in the absence of es-
trogen resulting in transcriptional activation of canonically
estrogen-dependent genes. By contrast, in the presence of
estrogen, ligand-bound AHR exhibits anti-estrogenic ef-
fects by suppressing estrogen-bound ESR-mediated DNA
binding. AHR may also be involved in cell-cycle regulation
through growth factor signaling, cell-cycle arrest, and
apoptosis.
In addition to increased proliferation, the cells that
comprise endometriotic lesions are thought to have de-
fects in apoptotic signaling pathways. AHR also interacts
with nuclear factor kappa-B (NF-κB) signaling pathways
[89-91]. The pleiotropic transcription factor, NF-κB has
been identified to protect cells from apoptosis. The pro-
tein is constitutively active in endometriotic cells and its
activation by lipopolysaccharide (LPS) can induce prolif-
eration of endometriotic cells [92]. B-cell lymphoma/
leukemia-2 (Bcl-2) is a well-known anti-apoptotic signal-
ing protein. In normal endometrium, Bcl-2 demonstrates
cyclical expression decreasing during the menstrual and
late proliferative phases, indicating hormonal regulation.
However, this regulation is lost in endometriosis [77].
Conversely, expression of the pro-apoptotic protein
Fas is unchanged while its ligand, FasL, is upregulated
in endometriotic tissue as well as the peritoneal fluid
of women with endometriosis [93,94]. There is evi-
dence to suggest that macrophage derived growth factors,
including platelet-derived growth factor and transform-
ing growth factor beta (TGF-β), may stimulate Fas medi-
ated apoptosis of immune cells, which may contribute
Figure 1 Transcriptional regulation of proliferation’s factors. NF-kB, STAT and SMADs are the main regulators of such factors as MMP-2,
MMP-9, MMP-7, leptin, HGF, TNF-alpha, which can stimulate proliferation of endometriotic lesions.
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tic cell survival [94]. Furthermore, upregulated expres-
sion of survivin, decreased terminal effector caspases
and DNA fragmentation factor 45 in endometriotic tis-
sues may be a reflection of resistance against apoptosis
at ectopic sites [77].
Watanabe et al. demonstrated that survivin plays a
critical role in susceptibility of endometrial stromal cells
(ESCs) to apoptosis [95]. Survivin treatment of ESCs
leads to a reduction of apoptosis inhibiting proteins, such
as cIAP-1, XIAP, and survivin as well as an increase of
apoptotic cells [95].
ESCs have been shown to be resistant to IFN- γ treat-
ment, which inhibits the proliferation and apoptosis of
EuSCs and NESC. Although the precise mechanism of
IFN- γ resistance is unknown, the presence of IFN- γreceptor in ECSC suggests that there is dysregulation
of subsequent intracellular signaling pathways in these
cells [96].
Adhesion and invasion
In order for endometriotic lesions to occur, the cells
must invade and implant in distant locations. Increas-
ingly, studies are noting roles for adhesions molecules
and growth factors in this process. Cells derived from
endometriotic lesions have increased adhesive capacity to
various components of the extra cellular matrix (ECM) in-
cluding collagen type IV, laminin, vitronectin, and fibro-
nectin, whereas normal endometrium is more specific
[77,97]. In fact, in the early stages of endometriosis, attach-
ment seems to be due to ECM degradation that could play
a key role in initiation of endometriosis [98].
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that promote cell attachment to the ECM proteins
thereby sustaining cell migration and invasion [99]. The
β-1 integrins and E-cadherin are both found in the
endometrium [99]. Aberrant expression of E-cadherin,
β-catenin, and integrins has been reported in endometri-
osis. β-catenin plays a role in cell-to-cell adhesion and
intracellular signaling binding to intracellular E-cadherin
and connecting E-cadherin to the cytoskeleton of the
cell [100]. The E-cadherin–β-catenin complex plays a
crucial role in epithelial cell–cell adhesion and in the
maintenance of tissue architecture [101]. Aberrant ex-
pression of cadherins and integrins is involved in initi-
ation and progression of human tumors [102]. In the
case of endometriosis, there are controversial reports
about expression levels of these adhesion proteins.
Poncelet et al. have reported reduced expression of
E-cadherin in ESCs [103]. Loss of E-cadherin expres-
sion may be related to the local aggressiveness and
invasiveness of peritoneal endometriotic lesions [101].
Indeed, Gaetje et al. found in an in vitro study using
peritoneal endometriotic biopsies that E-cadherin posi-
tive cells were devoid of invasive capacities whereas
E-cadherin negative cells were invasive [104]. Con-
versely, Ueda at al. did not find altered expression of
E-cadherins in peritoneal endometriotic lesions compared
to eutopic endometrium [102]. This data are supported by
other studies, which have also found high E-cadherin
expression in endometriotic lesions, with no differ-
ence compared to proliferative endometrium [101,105].
E-cadherin expression in endometrial cells has been re-
ported to be constant throughout the menstrual cycle
[105,106]. However, another study found that E-cadherin
mRNA was significantly lower at the proliferative phase
than at the secretory phase [107]. Thus, E-cadherin ex-
pression can probably be affected by menstrual cycle
phase and stage of endometriosis. Hereby, E-cadherin ex-
pression patterns in endometriotic tissues are contradict-
ory and the role of E-cadherin in the development and
progression of endometriosis is still unclear.
In recent studies, β-catenin has been shown to be
down-regulated in endometrioid carcinoma and reduced
β-catenin expression could be involved in the patho-
genesis of endometriosis contributing to its invasive
character. Others have suggested that increased ex-
pression of β-catenin and activation of Wnt/β-catenin
complex may be a molecular mechanism of fibrosis in
endometriosis [101,108,109].
Interestingly, endometriosis showed decreased β-catenin
expression compared with endometrioid carcinoma. This
implies that different alterations in the E-cadherin–β-
catenin complex contribute to the pathogenesis of endo-
metriosis and endometrioid carcinoma. It seems logical
that different changes in epithelial adhesion moleculesparticipate in the initiation and/or disease progression of
a benign as opposed to a malignant disease [99].
Wnt/β-catenin complex regulates stem cell pluripo-
tency and cell development, integrating signals from
other pathways, such as TGF- β and FGF (Fibroblast
growth factor), and targeting genes involved in cell mi-
gration and proliferation [110]. In particular, TGF- β has
been reported to be involved in the pathogenesis of
endometriosis, playing a critical role in migration and
proliferation of fibroblasts to develop endometriotic
lesions [108].
P-cadherin is the predominant cadherin subtype present
in the human peritoneum and P-cadherin mRNA has been
found to be significantly increased in peritoneal endome-
triotic lesions compared with eutopic endometrium, sug-
gesting that P-cadherin may be involved in mediating
endometrial–peritoneal cell interactions in the develop-
ment of endometriosis [111].
Integrins mediate adhesion of cells to ECM compo-
nents, such as collagen types I and IV, fibronectin, and
laminin. Integrins are a large family of transmembrane
glycoproteins that have a dimeric structure of α and β
subunits and act as receptors for ECM components.
There are several studies investigating the aberrant ex-
pression of integrins in endometriotic cells and their role
in the invasion and attachment of ESCs to different
components of the ECM [99]. Integrins β1 and β5 were
present in endometriotic lesions in a nude mouse model
and shown to be of peritoneal origin [112]. Higher levels
integrin of α1, α2, αv, β1, and β3 protein expression
were observed in ESCs than in (normal eutopic endo-
metrial cells) NESCs. On the other hand, the levels of
integrin α3 and αL proteins were lower in ESCs than
in NESCs [61]. Integrin α3β1 is weakly expressed in
menstrual endometrium and integrin α6β1is strongly
expressed, both have been characterized as the principal
laminin receptors. Blockage of the β6 subunit by a spe-
cific antibody has led to a significant reduction of adhe-
sion of ESCs to laminin and a smaller reduction to other
ECM components [113]. Adhesion to fibronectin is me-
diated by the α4β1, α5β1 and αvβ3 integrins. Blockage of
the β1 subunit and RGD (Arg-Gly-Asp) antibodies that
are involved in α5β1 and αvβ3 integrin function have not
prevented adhesion of ESCs to fibronectin. Blocking of
collagen receptors α1β1, α2β1, α3β1 did not reduce adhe-
sion of menstrual endometrial cells to collagen. These
data suggest that α6β1 could play a key role in early
phases of the development of the endometriosis [113].
Previous studies investigating the role of integrins in
menstrual endometrium attachment have not shown the
complete inhibition of adhesion to ECM components
that suggest other mechanisms to be involved [113].
Osteopontin (OPN) is a glycoprotein involved in cell
adhesion and migration by binding to integrins [114].
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endometrium of women with endometriosis [114]. OPN
is also speculated to influence migration and angiogen-
esis by regulating CD133+, also known as prominin-1,
progenitor cells [114]. The migration of these progenitor
cells is thought to contribute to the establishment of dis-
tant endometriotic lesions.
Octamer-binding transcription factor 4 (OCT4) is a
pluripotent factor that has been reported to be overex-
pressed in endometrial lesions [115,116]. The expression
of OCT4 may contribute to the pathology of ectopic
endometrial growth by stimulating the migration activity
of endometrial cells [115].
Matrix Metalloproteinases (MMPs) also contribute to
cell migration via break down of ECM components and
subsequent tissue remodeling. MMP-1, −2, −3, −7,
and −9 are upregulated in endometriosis and their
expression is induced by cytokines such as IL-1, IL-8,
and TNF-α [117,118]. Furthermore, expression of tissue
inhibitor of metalloproteinase-1 (TIMP-1) is decreased in
the peritoneal fluid of women with endometriosis [119].
TIMPs have been shown to control endometriotic cell
migration induced by MMPs, suggesting that its down-
regulation is a major factor in the pathophysiology of
endometriosis.
Angiogenesis
Just as observed for tumor growth, angiogenesis of le-
sions is essential for endometriotic cell survival and de-
velopment. The two main regulators of angiogenesis are
vascular endothelial growth factors (VEGF) and angio-
poietins [120] [Figure 2]. VEGF is a key regulator of
both physiological and pathological angiogenesis. VEGF
is significantly increased in the peripheral blood, peri-
toneal fluid, and endometrium of patients with endo-
metriosis and its expression is known to be stimulated
by a variety of cytokines, including IL-1 [121]. Inhib-
ition of VEGF has been shown to lead to a significant
decrease in the number of endometriotic lesions [122].
Angiopoeitin-1 (Ang-1) and Ang-2 are both increased
in the endometrium of patients with endometriosis
[120,123]. Ang-1 stimulates new vessel formation and
Ang-2 can loosen cell-cell and cell-ECM contacts resulting
in vessel remodeling.
Glycodelin is an endometrium-derived protein known
for its angiogenic, immunosuppressive, and contracep-
tive effects. Glycodelin is thought to be involved in both
the development of endometriosis and the infertility as-
sociated with the disease [124].
Glycodelin produced in the glandular epithelium of
secretory endometrium and is shed from endometriotic
lesions into the peritoneal fluid and serum.
These findings indicate that proangiogenic factors have
pivotal roles in the pathogenesis of endometriosis [125,126].Altered immune function
Some theories suggest that the immune system must be
at least partially compromised to allow the development
of ectopic endometriotic lesions. Macrophages play an
especially important role being the predominant leuko-
cytes found in the peritoneal fluid of women with endo-
metriosis [71,127]. They have been shown to be involved
in ectopic endometrial cell adhesion, implantation, and
growth. Moreover, the secretory products of macro-
phages are also significantly increased in both the peri-
toneal fluid of patients with endometriosis as well as in
the endometriotic lesions.
One of the major secretory products of macrophages
is TGF-β, which is known to play a role in increasing
the rate of post-surgical adhesion formation suggesting
that it may also play a role in endometriotic cell adhe-
sion [77]. IL-1 is a macrophage derived cytokine that
can induce expression of COX-2 and IL-8, thereby likely
playing a role in proliferation, migration, as well as
angiogenesis of endometriotic lesions [83]. Many of the
genes involved in endometriosis are implicated in aging
[128]. HGF is also upregulated in endometriotic lesions.
HGF can be upregulated by LPS-stimulated macro-
phages in endometriotic lesions and subsequently enhance
proliferation of endometriotic cells [129]. Macrophages
are also potential sources of the increased VEGF in pa-
tients with endometriosis. Studies in mouse models dem-
onstrate that after implantation of uterine tissues into the
peritoneum, macrophages are activated and VEGF is se-
creted in response to TNF-α and IL-6 [127].
Prostaglandin-E2 (PGE2) is another secretory product
of macrophages that is also produced by ectopic endo-
metrial cells [130,131]. PGE2 plays multiple roles in the
pathophysiology of endometriosis via signaling through
four receptors. Firstly, PGE2 increases estrogen synthesis
by up regulating steroidogenic acute regulatory protein
(StAR) and aromatase [130]. PGE2 in combination with
IL-4 may enhance estrogen production in endometriotic
tissues, implying an elaborate mechanism by which the
Th2 immune response augments inflammation-dependent
progression of the disease [131]. Furthermore, through its
effect on estrogen and up regulation of VEGF, PGE2 affects
leukocyte populations and promotes angiogenesis. It also
inhibits apoptosis and up regulates fibroblast growth
factor-9 (FGF-9) to promote cell proliferation.
Lastly, macrophage migration inhibitory factor (MIF)
is a cytokine that is a major immune regulator as well as
a potent angiogenic and tissue remodeling factor. MIF is
significantly increased in endometriotic lesions and is
likely upregulated by IL-1 in this context [132].
Natural Killer (NK) cells are a major component of
immune surveillance and NK cell activity in the periton-
eal fluid can suppress formation of ectopic lesions [133].
Therefore, it follows that their activity is decreased in
Figure 2 VEGF and angiopoietin – two main regulators of angiogenesis. Angiogenesis of lesions is essential for endometriotic cell survival
and development. Signaling pathways of VEGF and angiopoietin intersect at PI3K.
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Soluble intercellular adhesion molecule-1 (sICAM-1),
one of the major adhesion molecules that inhibits nat-
ural killer cell–mediated cytotoxicity, is involved in the
implantation and development of endometriotic lesions
[135,136]. Studies have confirmed changes in sICAM-1
levels in women with endometriosis compared with
controls [137,138].
Endometriosis is an inflammatory disease associated
with abnormal T-cell function. IL-4, a cytokine produced
by helper T-cells (Th) is significantly upregulated in
endometriotic lesions and can stimulate the prolifera-
tion of endometriotic cells [139]. Th17 cells are also
enriched in the peritoneal fluid of women with endo-
metriosis as well as the ectopic endometrium. IL-17
has been shown to stimulate IL-8 and COX-2 expres-
sion thereby enhancing proliferation and migration of
endometriotic cells [140].Monocyte chemotactic protein-1 (MCP-1) is a mem-
ber of the small inducible gene family, which plays a role
in the recruitment of monocytes to sites of injury and
inflammation [141]. Levels of MCP-1 are increased in
the peritoneal fluid and serum of women with endomet-
riosis, particularly in patients with early disease [142].
Lastly, mast cells are the major effectors of allergic re-
sponses and have been found in increased numbers in
ectopic endometrium [77]. Mast cells are likely associ-
ated with the fibrosis and adhesion of the lesions. Based
on rat models, there is a strong correlation between
endometriosis and allergies [77].
Perhaps the most important component of immune
dysregulation in endometriosis is mediated by the major
histocompatibility complex (MHC). The MHC, also known
as Human Leukocyte Antigens (HLA), are cell surface pro-
teins that mediate interactions between immune respon-
sive cells. Aberrant expression of both Class I and II MHC
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activity of NK cells [143,144]. Some studies have sug-
gested that the class I antigens HLA-B*07 and B*46
are associated with the development of endometriosis,
whereas HLA-B*48 may offer a protective effect [145,146].
Additionally, the class II HLA-DR antigens are aberrantly
expressed in glandular cells of endometrium in endometri-
osis and adenomyosis and are thought to be involved
in various immunological abnormalities [147,148]. Non-
classical HLA-G proteins have been suggested to be
expressed on ectopic endometriotic cells and to play
a critical role in the development of endometriosis though
the suppression of NK function [149,150]. However, other
studies have reported that HLA-G is not expressed by
endometrial cells at all [151].
Despite what is known about altered MHC expression,
it is equally plausible that abnormalities in NK receptors
could lay the basis of altered immune response in endo-
metriosis. For example, polymorphisms in killer cell
immunoglobulin-like receptors (KIRs) may be associated
with susceptibility for endometriosis [152].
MicroRNA
MicroRNAs (miRNAs) are naturally occurring posttran-
scriptional regulatory molecules that potentially play a
role in endometriotic lesion development [Figure 3]. In
one study, 22 endometriosis-associated miRNAs were
identified by microarray analysis in paired ectopic and
eutopic endometrial tissues [153]. Of these, 14 were
found to be up-regulated (miR-145, miR-143, miR-99a,
miR-99b, miR-126, miR-100, miR-125b, miR-150, miR-
125a, miR-223, miR-194, miR-365, miR-29c and miR-1)
and 8 down-regulated (miR-200a, miR-141, miR-200b,
miR-142-3p, miR-424, miR-34c, miR-20a and miR-196b)
miRNAs [153]. Functional analysis indicated that 673
miRNA targets constitute molecular pathways involved
in the development of endometriosis, including c-Jun,
CREB-binding protein, protein kinase B (Akt), and
cyclin D1 (CCND1) signaling [141]. Another study found
10 microRNAs that were up-regulated (miR-202, 193a-
3p, 29c, 708, 509-3-5p, 574-3p, 193a-5p, 485-3p, 100,
and 720) and 12 that were down-regulated (miR-504,
141, 429, 203, 10a, 200b, 873, 200c, 200a, 449b, 375,
and 34c-5p) in endometriosis compared with normal
endometrium [154].
A number of miRNAs are regulated by 17β estradiol
and progesterone in the endometrial epithelial and stro-
mal cells, including miR-20a, miR-21, miR-23, miR-26a,
miR-18a, miR-181a, miR-206, and miR-142-5p. These
miRNAs have been predicted to target the expression of
a large number of genes, including transforming growth
factor β (TGF-β), TGF-β receptors, ERs, PRs, and CYP-
19A1 (aromatase), many of which are known to play
critical roles in endometrial activities [155].Additional studies have explored individual miRNAs
in eutopic endometrium from women with endomet-
riosis. Compared with healthy controls, endometrium
from women with endometriosis is characterized by
over-expression of miR-135a in the proliferative phase
and miR-135b in the proliferative and secretory phases
[156]. These miRNAs were predicted and validated to
target HOXA10, a key mediator of endometrial receptiv-
ity, the expression of which was simultaneously repressed
in the endometrium of women with endometriosis [157].
Transfection of ESCs with miR-135a/b or miR-135a/b
inhibitors resulted in altered expression of HOXA10
mRNA and protein and this may suppress endometrial
receptivity in endometriosis [157].
Transfection of ESCs with miR-199a repressed IκB
kinase/NFκB signaling and inhibited IL-8 secretion.
Therefore, the low expression levels of miR-199a in
ESCs from women with endometriosis would be ex-
pected to up-regulate these inflammatory mediators and
result in decreased endometrial receptivity and implant-
ation defects [158].
Decreased miR-20a and miR-200b may contribute to
the up-regulation of CREB binding protein (CREBBP)
mRNAs in endometriosis [159]. CREBBP is a co-activator
of hypoxia inducible transcription factor 1a (HIF1a), a hyp-
oxia induced and pro-angiogenic transcription factor.
CREBBP/HIF1a activities are likely to be increased in ec-
topic endometriotic lesions due to loss of transcript sup-
pression by downregulation of miR-20a and miR-200b.
Reduced repression of HIF1a mRNA translation by miR-
20a is consistent with the elevated HIF1a mRNA levels
seen in endometriotic lesions. CREBBP was also central in
one of our miRNA regulated pathway networks associated
with angiogenesis in endometriosis.
Both HIFa and NFκB can be activated by elevated
levels of IL-1β and TNFα in endometriosis. This process
can lead to enhanced COX-2 transcription [160]. COX-2
participates in a positive feed forward loop that en-
hances aromatase activity and local estradiol production
in endometriotic lesions, thereby promoting a prolifer-
ative local hormonal environment. COX-2 translation
is known to be suppressed by miR-199a and miR-16
and both of these miRNAs were down-regulated in
endometriosis [155,161].
Apoptotic resistance is mediated by BCL2, leading to
enhanced survival of stressed endometrial cells in endo-
metriosis. BCL2 is targeted by miR-15b/16 and the
reduced expression of these miRNAs may contribute
to increased activity of this anti-apoptotic protein in
endometriosis [162]. Furthermore, cell proliferation is
promoted by the cell cycle regulator insulin receptor
substrate-1 (IRS1). Two highly up-regulated miRNAs in
endometriosis, miR-126 and miR-145, target this mitogenic
protein and may inhibit endometrial cell proliferation
Figure 3 MicroRNA involved in endometriosis. MicroRNAs (miRNAs) are naturally occurring posttranscriptional regulatory molecules that
potentially play a role in endometriotic lesion development. A number of miRNAs are regulated by 17β-estradiol in the endometrial epithelial
and stromal cells, including miR-21, miR-23a, miR-26a-1, miR-203, miR-181a, miR-424, and miR-34c. MicroRNA-15b, miR-126 have been predicted
to target the expression of VEGF-A; miR-34c-5p – the expression of EGF.
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seen in endometriotic tissues may ease post-transcriptional
suppression of their mRNA targets, which include the
cell cycle repressors cyclin-dependent kinase inhibitors
CDKN1A/p21, CDKN1B (p27), and CDKN1C (p57).
High miR-15b/16, miR-143, miR-145 and low miR-20a,
miR-221 and miR-222 expression are consistent with
repressed cell proliferation and enhanced cell survival
in endometriosis [163].
Endometriotic lesion development has been associated
with an aberrant expression of ECM proteins. Upregula-
tion of miR-29c in endometriotic tissue may control the
ECM production that is integral to endometriotic lesion
development [153]. Precise organization of the ECM
scaffold may be crucial for the correct placement of de-
veloping glands and stroma in remodeling tissues and
miRNAs may contribute by fine tuning this process.
In endothelial cells, miR-126 enhances VEGF and FGF
signaling, leading to neoangiogenesis and the develop-
ment of mature vasculature [164]. miR-126 is embedded
in the EGF-like-domain, multiple 7 (EGFL7) gene andboth of these transcripts are highly up-regulated in ec-
topic versus eutopic endometrium, which is indicative of
co-transcription [153,165]. EGFL7 enhances the effect of
miR-126 by inducing endothelial cell migration during
neovascularization [166].
Screening and diagnostic techniques
Monitoring endometriosis in a clinical setting
Definitive diagnosis of endometriosis is notoriously dif-
ficult. Laparoscopy is currently the gold standard for
diagnosis [167]. Endometriosis manifests in peritoneal
congestion, adhesions, and other defects, which are readily
observed by laparoscopy. Additionally, if laparoscopic find-
ings are suspicious a biopsy can be obtained. Histological
diagnosis of endometriosis, while confirmative, is often dif-
ficult [168]. Indeed, the sensitivity and specificity of either
laparoscopy or biopsy are not sufficient to justify routine
clinical use either for diagnosis or monitoring. Further-
more, both of these techniques are invasive and, therefore,
present a major barrier to effective clinical management of
endometriosis.
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particular, MR imaging are increasingly used to diagnose
the presence and extent of infiltrating lesions [167].
Transvaginal sonography is useful in the diagnosis of
ovarian endometriomata and a pelvic sonogram or ultra-
sound can detect endometriosis cysts of the ovaries.
However, none of these methods are effective to detect
endometriotic lesions in the pelvis because endometri-
osis can look similar to other kinds of ovarian cysts on
sonogram. Thus, a surgical evaluation is required if the
cyst persists throughout 2 menstrual cycles.
For these reasons, development of sensitive and spe-
cific non-invasive tests for endometriosis is a priority for
investigators [169]. Many DNA-based non-invasive diag-
nostics methods are used in the clinical practice in ob-
stetrics and gynecology [170]. A noninvasive test would
be useful for early detection and staging of endometri-
osis in symptomatic women who have pelvic pain and/or
subfertility with normal ultrasound results. Currently, there
are several diagnostic tests including panels of known per-
ipheral blood biomarkers, protein/peptide markers, and
miRNAs. However, no reliable blood test for endometriosis
exists [171]. Nonetheless, with the maturation of genomic
and proteomic technology we are closer than ever to iden-
tifying a blood test for rapid and reliable diagnosis of this
debilitating disease. So far, studies have focused on glyco-
proteins, cytokines, adhesion molecules, as well as angio-
genic and growth factors, which are all associated with the
pathogenesis of endometriosis and the development of
endometriotic lesions [171].
Biomarkers such as annexin V, vascular endothelial
growth factor (VEGF), CA-125, and soluble intercellular
adhesion molecule-1 (sICAM-1/or glycodelin) [Figure 4]
in plasma samples have been shown in the multivariate
analysis to diagnose endometriosis that was undetectable
by ultrasound with a sensitivity of 81% to 90% and a spe-
cificity of 63% to 81% [171]. Specifically, cancer antigen
125 (CA-125) has come into common use as a periph-
eral biomarker of endometriosis [172]. CA-125 is known
to be produced by endometrial and mesothelial cells and
enters the circulation in response to inflammation via
the endothelial lining of capillaries. Moderate elevation
of serum CA125 has been observed in endometriosis,
particularly in patients with severe disease [173,174].
However, CA-125 levels in peripheral blood lack diag-
nostic power as a single biomarker of endometriosis due
to low sensitivity [172].
Studies investigating of serum cytokines as biomarkers
have demonstrated significant elevation of levels of
interleukin-6, monocyte chemotactic protein-1, and
interferon-gamma in serum of subjects with endometri-
osis compared to healthy women. However, the authors
suggest that only IL-6 provides a promising serum
marker for nonsurgical diagnosis of endometriosis becauseIL-6 has higher specificity alone then when adding serum
IL-6, MCP-1, and INF-g together. Additionally, IL-6
levels did not change during any phase of the menstrual
cycle [175]. A study by Wang et al. demonstrated that
the circulating miRNAs miR-199a, miR-122, miR-145*,
and miR-542-3p could potentially serve as noninvasive
biomarkers for endometriosis [146]. This was the first re-
port that circulating miRNAs serve as biomarkers of
endometriosis.
One potential method for analyzing the differences
between the stages of endometriosis in order to per-
sonalize treatment is to apply gene expression analysis
and measure the signaling pathway activation profiles
[176,177], which could be considered for further inves-
tigation of possible personalized science research projects
[178]. It is possible that different subsets of biomarkers
may be required for the diagnosis of different stages of
endometriosis.
Epigenetics of endometriosis
The word ‘epigenetics’ refers to the study of heritable
changes in gene expression that occur without changes
in the DNA sequence [179], which includes mechanisms
such as DNA methylation, histone modification, and
transcription factor regulation [180]. Cancer and many
other diseases show aberrant epigenetic regulation [181].
There is accumulating evidence to support the etiology
of endometriosis as an epigenetic disease [182,183]. How-
ever, much remains to be studied in order to fully evalu-
ate the role of epigenetic factors in the development of
endometriosis.
DNA methylation is the best understood and currently
most extensively studied epigenetic mechanism. The
modification, specifically the attachment of a methyl
group to the 5-carbon position of cytosine bases, oc-
curs within the CpG dinucleotides and is mediated
by DNMTs [184,185]. DNA methylation plays an im-
portant role in cellular processes and regulation of gene
expression and DNA methylation at CpG islands is
invariantly associated with gene silencing. The methyl-
ated CpGs are docking sites for silencer-type transcrip-
tion factors that contain a methyl CpG-binding domain
(MBD) [186]. DNMTs are divided into two main categor-
ies: enzymes involved in the maintenance of DNA methy-
lation (DNMT1) and enzymes involved in de novo DNA
methylation (DNMT3A and DNMT3B) [187]. The over-
expression of the DNMTs may be a prerequisite for
DNA hypermethylation [188]. DNMT1, DNMT3A and
DNMT3B are overexpressed in the epithelial component
of endometriotic implants. In contrast, only DNMT3A
was found to be upregulated in the eutopic endometrium
of women with endometriosis [189]. A positive correlation
has been noted among these three DNMTs. The up-
regulated expression of DNMTs in endometriotic tissue
Figure 4 Intracellular regulation of TNF-alpha, VEGF-A, sICAM1 and annexin V. VEGF-A may activate annexin V, a marker of apoptosis,
through VEGFR-2. TNF-alpha is regulated by such transcriptional factors as VDR, GATA-3, and NF-kB and is involved in signaling pathways of many
growth factors. sICAM1, one of the adhesion molecules involved in the implantation and development of endometriotic lesions, is activated by
NF-kB. There are a lot of drugs that have an effect on TNF-alpha, annexin V, VEGF-A and might be potentially used in the treatment of endometriosis.
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endometriosis. Several factors have been reported to in-
duce DNA methylation, including aging, diet, chronic in-
flammation, prolonged transcriptional suppression, and
environment [190-193]. These aberrations are likely to be
responsible for observed phenotypic aberrations at hormo-
nal, biochemical, inflammatory, immunologic, angiogenic,
apoptotic, and, ultimately, clinical levels in endometriosis,
which are manifested as the excessive local production of
estrogen and prostaglandin, inflammation, development of
progesterone resistance, altered apoptotic mechanisms,
and implantation failure. Because endometriosis is a per-
sistent disease, it is speculated that chronic inflammation, a
feature of endometriotic tissue, may induce aberrant DNA
methylation [194]. However, the aging cell undergoes a
DNA methylation drift. Early studies showed that global
DNA methylation decreases during aging in many tissue
types [195]. Several specific regions of the genomic DNA
become hypermethylated during aging [196]. Interestingly,
genes with increased promoter methylation during aging
include the E-cadherin gene, which is downregurated and
hypermethylated in endometriotic cells [197,198].
There has been a revolution in DNA methylation ana-
lysis technology [194]. A number of aberrantly expressed
genes have been reported in endometriosis, which couldbe related to aberrant DNA methylation [199,200]. Par-
ticularly, ERβ up-regulation in endometriotic cells may
be related to the hypomethylation of the ERβ-promoter
region and decreased PR-B expression in endometriotic
tissue could be related with the hypermethylated pro-
moter region of PR-B gene [201,202]. Aromatase is a key
molecule for estrogen production and has been demon-
strated to be regulated by DNA-methylation in endo-
metriosis [194]. Unmethylated CpG islands within the
aromatase gene in endometriotic cells may lead to its
up-regulation [194,203]. Downregulation of E-cadherin
has been shown in endometriotic cells and may occur due
to hypermethylation at the promoter region [198,204].
Steroidogenic factor-1 (SF-1) is a transcriptional factor
essential for estrogen biosynthesis and has aberrant ex-
pression in endometriotic lesions compared to eutopic
endometrium [205-207]. Increased expression of SF-1 in
endometriotic cells is related to demethylation of the
SF-1 gene promoter that leads to interaction with SF-2,
which activates its transcription in endometriotic cells.
On other hand, demethylation of the SF-1 gene promoter
excludes binding of transcription factor MBD2, which
prevents its interaction with transcriptional activators,
resulting in silencing of the SF-1 gene [208]. SF-1 expres-
sion in endometriosis may enhance aromatase expression
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endometriosis, HOXA10 expression is significantly de-
creased in the eutopic endometrium during the secretory
phase, indicating functional defects in uterine receptivity
[157,209]. The promoter region of HOXA10 gene was
found to be hypermethylated in the eutopic endometrium
of women with endometriosis and may be a cause of
HOXA10 downregulation [157,210]. Using the epigenetic
concept as the lens, new diagnostic markers or therapies




Hormone therapy for endometriosis is frequently effective
at reducing or even eliminating the pain of the disease
[211]. The primary mechanism of action of hormone ther-
apy is to inhibit estrogen production [211].
The success of various hormonal therapies depends on
the localization and type of the endometriotic lesions.
Superficial peritoneal and ovarian implants seem to re-
spond better to hormone therapy than deep ovarian or
peritoneal lesions or lesions within organs [211]. More-
over, hormone treatment has no effect on adhesion of
endometriotic cells and cannot improve fertility. None-
theless, a number of hormonal agents remain the main-
stay of endometriosis therapy.
Prostaglandin synthetase inhibitors (PGSIs)
PGSIs are a heterogeneous group of non-steroidal in-
flammatory agents that inhibit the production of prosta-
glandins [212]. PGSIs are effective in the early stages of
endometriosis, but lose efficacy when symptoms become
more severe [212]. Nevertheless a lot of side effects such as
skin reactions, bronchospasm, and serious blood dyscrasias
have been reported for several of these drugs [213].
Levonorgestrel intrauterine system
The levonorgestrel intrauterine system (LNG-IUS) is a
long-acting contraceptive method, which acts through a
steady low level of LNG in the peripheral circulation. The
LNG-IUS appears to have a direct effect on the growth of
endometriotic deposits through peritoneal fluid [214]. The
suppression of menstruation, or marked reduction of flow,
may also be beneficial in reducing the amount of retro-
grade menstruation. One of the side effects of the LNG-
IUS is thinning of the endometrium, which causes a de-
crease in menstrual blood loss and a high incidence of
amenorrhea. Thereby the LNG-IUS is used as a treatment
for dysmenorrhea, menorrhagia and endometriosis [215].
A study comparing LNG-IUS with expectant manage-
ment demonstrated significantly lower pain scores in the
LNG-IUS participants at 12 months [216]. In the second
trial LNG-IUS was compared with a GnRH analogueand found to be equally effective in reducing pain scores
after 6 months [217].
Oral contraceptives (OCPs)
OCPs contain both estrogen and progesterone and regu-
late the monthly development of the endometrial lining.
Use of OCPs has been suggested to reduce or eliminate
the pain associated with endometriosis, making them an
attractive long-term treatment option [12]. The most
common side effects of OCP treatment are acne, weight
gain and irregular withdrawal bleeding [218].
Gonadotropin-releasing hormone (GnRH) agonists
GnRH analogues are synthetic hormones that cause an
artificial menopause via inhibition of luteinizing hor-
mone (LH) and follicle stimulating hormone (FSH),
which in turn decreases estrogen levels preventing men-
struation. They can be administered as a nasal spray, by
injection, or as an implant [211]. GnRH agonist treat-
ment can force endometriosis into long term remission
[219,220]. However, this is at the expense of infertility
and other side-effects reminiscent of menopause such as
hot flashes, vaginal dryness, and bone loss [211,221]. These
side-effects can be minimized by co-administration of a
low-dose estrogen or progestin hormone replacement ther-
apy (HRT). Infertility resolves shortly after discontinuation
of the medication.
Progestogens
Progestogens are synthetic progesterone analogues that
prevent ovulation. Both injectable progestogens such
as medroxyprogesterone (Depo-Provera) and intrauter-
ine systems (Mirena) have been successfully used to treat
endometriosis [211]. The most common side effects are
irregular menstrual periods, stopping of menstrual bleed-
ing, weight gain.
Antiprogestogens
Also known as synthetic testosterone derivatives, anti-
progestogens are synthetic hormones that bring on an
artificial menopause by decreasing the production of
estrogen and progesterone. Antiprogestogens suppress
the growth of the endometrium and the symptoms of
endometriosis by blocking the production of ovarian-
stimulating hormones (LH and FSH) [211]. Side effects
of antiprogestogens comprise acne, weight gain, mood
changes and the development of masculine features such
as hair growth and a deepening voice.
Bioinformatics analysis
Genome wide association studies (GWAS) – genetic
biomarkers
There are four GWAS for endometriosis susceptibility cur-
rently listed in the National Human Genome Institute’s
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population primarily of Japanese ancestry [222,224,225].
The GWAS listed in the catalog include only those publi-
cations attempting to query at least 100,000 single nucleo-
tide polymorphisms (SNPs) in the initial stage. There are
also ~20 GWAS that are not listed in the catalog. However,
the clinical utility of defining SNPs in endometriosis re-
mains questionable. It is likely that SNP-based testing for
endometriosis will convey insufficient diagnostic power
and will have be combined with protein biomarkers identi-
fied from transcriptome analyses.
Transcriptome studies
We analyzed the available microarray data in order to
identify differentially regulated signaling pathways that
may be involved in the pathogenesis of endometriosis.
Further analysis of these pathways may reveal proteins,
peptides, or mRNAs that may be useful as biomarkers of
the disease or as potential therapeutic targets.
Signal transducers and activators of transcription (STATs)
Network analysis revealed that signal transducers and
activators of transcription (STAT) proteins formed a
central node of regulation for a majority of the pathways.
STATs are a family of seven transcription factors thatFigure 5 STAT1 as an integral factor of IGF, HGF, EGF, IL-6, and PDGF sig
factors and regulate proliferation and apoptosis. A number of growth factors a
derived from endometriotic lesions. The effects of such factors as EGF, PDGF, Freside in the cytoplasm in the inactivated form. The
STATs can be divided into two groups based on func-
tion. The first group, STAT2, 4, and 6, are activated by
cytokines and are involved in T-cell development in
IFN-γ signaling [226]. STAT1, 3, and 5 are primarily ac-
tivated by growth factors and regulate proliferation and
apoptosis [226]. A number of growth factors are known
to contribute to the increased proliferative potential of
cells derived from endometriotic lesions. The effects of
EGF, PDGF, FGFR, IL-6, HGF and VEGF are all primar-
ily achieved through STAT activation [Figure 5].
STATs are latent transcription factors that reside in the
cytoplasm. They are primarily activated via C-terminal
phosphorylation by Janus kinase (JAK), which induces
nuclear translocation of STAT via importin α-5 and the
Ran nuclear import pathway [227]. However, some
growth factor receptors, including EGFR, HGFR, and
PDGFR, have intrinsic tyrosine kinase activity allowing
them to directly phosphorylate and activate STAT [228].
Once in the nucleus, dimerized STATs bind specific regu-
latory sequences to activate or repress the transcription
of target genes [227]. STATs mediate effects through
transcriptional activation of target genes that enhance
proliferation (CCND1 and c-Myc), angiogenesis (VEGFA,
ADM and ANGPTL4), invasion (FGA, FGB, CTSB andnaling pathways. STAT1, 3, and 5 are primarily activated by growth
re known to contribute to the increased proliferative potential of cells
GFR, IL-6, HGF and VEGF are all primarily achieved through STAT activation.
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Mcl-1 and Survivin) [229] [Figure 6].
STAT5 regulates the genetic transcription of cyclins
and constitutive activation of STAT5 deregulates the
cyclin complexes D/CDK4-6, which control progression
from the G1 to the S-phase of the cell cycle [230]. Fur-
thermore, the constitutive activation of STAT5 induces
antiapoptotic signals including Bcl-xL [231].
Alternatively, no STAT3 mutations inducing constitu-
tive activation have been identified. Rather, dimerized
mutant forms called STAT3C, which require no phos-
phorylation to become active, are able to migrate to the
nucleus, guide transcription, and induce cell transform-
ation [232]. As with STAT5, the constitutive activa-
tion of STAT3 both induces proliferation and inhibits
apoptosis. STAT3 plays an important role in the G1-SFigure 6 Intracellular interactions of estradiol, androgens and prolact
through the STATs. STAT1 and STAT3 contribute to the implementation ofcell-cycle transition since it upregulates cyclins D (D1, 2, 3)
and A (cdc25A), and downregulates p21 and p27 [233].
STAT3 can also activate proangiogenic factors such as
VEGF [234].
Since endometriosis develops through mechanisms
that include proliferation, inhibition of apoptosis, migra-
tion, and angiogenesis, it is feasible that STATs may play
a key role in the pathogenesis of endometriosis as a mas-
ter regulator of many of these pathways.
SMAD transcription factors
Other key regulators mediating growth factor pathways are
the SMAD transcription factors. The SMAD proteins are
the only family of transcription factors known to propagate
TGF-β signals. However, they also regulate other growth
factor pathways, including PDGF, VEGF, and HGF [235].in. Estradiol, androgens and prolactin signaling pathways also pass
their effects.
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proliferation through the phosphorylation of SMADs,
which induces their nuclear translocation [236]. Acti-
vated TGF-β phosphorylates the R-SMADs (receptor
activated), which includes SMAD2 and SMAD3. Phos-
phorylated R-SMADs bind to SMAD4 and translocate to
the nucleus as a complex [236]. SMAD4 is required for the
formation of an active transcriptional complex [237].
A diverse array of genes is subsequently regulated by
SMAD signaling. Proliferation signals under the transcrip-
tional control of TFG-β and SMADs include cyclin-D1,
cyclin-dependent kinase 4, p21, p27, p15, and c-myc [238].
TGF-β is well known to be a pro-apoptotic protein, regu-
lating expression of Bad and caspase-3 [239]. Additionally,
ECM proteins including fibronectin, collagen, and MMPs,
are also regulated by SMAD signaling [238,239].
In addition to all of these pathways, which are fairly
well understood in relation to TGF-β/SMAD signaling,
this key regulatory node may also contribute to a com-
promised immune status, which allows for formation of
endometriotic lesions. Firstly, TGF-β secretion from in-
creased numbers of macrophages in the peritoneal fluid
of women with endometriosis can induce expression ofFigure 7 JAK/STAT signaling pathway in endometriosis. The effects of
activation. The JAK/STAT pathway is a tempting target for novel therapeuti
translation of extracellular signals into a transcriptional response. Of the pa
STATs. Among the small molecule inhibitors of this pathway are Leflunomimonocyte chemoattractant protein-1 (MCP-1) as well as
COX-2 and PGE2. The upregulation of these signals re-
sults in a chronic inflammatory response [239]. Further-
more, SMAD-deficient mice have demonstrated defects
in T-cell differentiation leading to an imbalance of ef-
fector and regulatory lymphocytes. Loss of immune sys-
tem homeostasis could contribute to the pathogenesis of
endometriosis [240].
MEK/ERK
Perhaps the most crucial signaling node identified in our
studies is the mitogen-activated protein kinase (MAPK)/
extracellular signal-regulated kinase (ERK) or MEK path-
way. This pathway has been extensively studied over the
past few decades and has well defined roles in regulation
of signaling for proliferation, apoptosis, adhesion, inva-
sion, angiogenesis, and evasion of immune surveillance
[241,242]. ERK controls transcriptional expression of
c-myc and c-Fos, which are both involved in cell-cycle
progression and cellular proliferation [243]. In the cyto-
plasm, ERK is responsible for the regulation of the
ribosomal S6 kinase (RSK) family proteins, which subse-
quently regulate cell-cycle progression via expression ofPDGF, FGF, IL-6, HGF, and VEGF are all primarily achieved through STAT
cs because it is relatively simple mechanistically, providing a direct
thways identified, perhaps the most viable as a biomarker are the
de (a JAK inhibitor) and Atiprimod (a STAT3 inhibitor).
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http://www.rbej.com/content/12/1/50p27, apoptosis via inhibition of Bad, as well a number of
other signaling cascades via the transcription factors
NF-κB and estrogen receptor-α [243]. ERK also has effects
on the ECM via regulation of the actin-binding protein
paladin [243]. The contribution of MEK/ERK to cell adhe-
sion, migration, and invasion is partly mediated through
its regulation of the down-stream TGF-β/SMAD pathway
[242]. Lastly, the MEK/ERK pathway has been suggested
to contribute to evasion of immune surveillance by pro-
moting the downregulation of cell-surface antigens that
would be recognized by T-cells [242].
The MEK/ERK pathway is upstream of many of the
other signaling nodes identified in our analysis, which
indicates that it may be a master regulator of the major-
ity of the signaling pathways and cascades involved in
the pathogenesis of endometriosis and, therefore, highly
important as a potential therapeutic target [241].
Prospective biomarkers
A great deal of research has recently been devoted to the
identification of biomarkers for diagnosis of endometriosis.
While some putative candidates have been identified, theyFigure 8 TGF-β/SMAD signaling pathway. The SMAD proteins are the o
Lerdelimumab (a recombinant human IgG4 targeting TGF- β2) and Metelim
TGF-β signaling.lack sufficient sensitivity and specificity to be clinically use-
ful. The results of our bioinformatics analysis align with
those previous findings in that the pathways identified are
ubiquitous key regulatory pathways. As such, they are in-
volved in numerous signaling cascades controlling cell pro-
liferation, apoptosis, invasion, and have implications in a
variety of disease processes.
We used Metacore software for bioinformatics analysis
of the main signaling pathways involved in pathogenesis of
endometriosis. Metacore software provides an opportunity
to model disease pathways and targets allow assessment of
biomarkers. Of the pathways identified, perhaps the most
viable as a biomarker are the STATs. A meta-analysis of
biomarker studies identified numerous cytokines as being
potentially diagnostic for endometriosis [172]. Many of
these cytokines transduce signals through STATs. There-
fore, STATs may serve as a convergent, and thereby more
sensitive, readout of cytokine status.
Prospective treatment methods
In addition to their potential role as biomarkers of
endometriosis the signaling molecules and pathwaysnly family of transcription factors known to propagate TGF-β signals.
umab (a human monoclonal IgG4 against TGF- β1) can inhibit
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new therapies.
JAK/STAT The JAK/STAT pathway is a tempting target
for novel therapeutics because it is relatively simple
mechanistically, providing a direct translation of extra-
cellular signal into a transcriptional response. There are
several small molecule drug candidates that have been
shown to regulate the JAK/STAT pathway and several
are already on the market while others are still in clinical
trials [244].
Leflunomide is a JAK inhibitor that is used to treat
rheumatoid arthritis (RA) and fibrosis. In model cell lines,
leflunomide primarily inhibits cell migration through in-
hibitory effects on ECM proteins such as collagen [244].
Though it has also been shown to block cell proliferation
through various JAK mediated pathways [Figure 7].
Atiprimod is a STAT3 inhibitor currently in clinical
trials. In multiple myeloma cells lines it has been shown
to induce apoptosis via cleavage of caspase-3 and down-
regulation of Bcl-2 [244]. Furthermore, it has been shown
to have anti-inflammatory effects in animal models of RA
via inhibition of IL-6 production [244].
TGF-β/SMAD Novel therapeutics aimed at inhibition of
the TGF-β/SMAD pathway have taken three forms:Figure 9 Interactions between MEK, c-Myc, c-Fos and growth factors.
Selumetinib and other MEK/ERK inhibitors are being primarily develope
MEK/ERK-pathway in endometriosis suggests that these therapeutic stra(1) translational inhibition using antisense oligonucleotides,
(2) inhibition of the ligand/receptor interaction using
monoclonal antibodies, and (3) small molecule inhibitors
of the signaling cascade [245]. Several antisense oligo-
nucleotide therapies are in clinical trials and have dem-
onstrated great efficacy in cell models. However, thus far,
clinical results have been disappointing [245]. Alterna-
tively, several monoclonal antibodies have shown signifi-
cant promise.
Lerdelimumab is a recombinant human IgG4 targeting
TGF-β2, which is currently in clinical trials for treatment
of post-surgical fibrosis [245]. Metelimumab is a human
monoclonal IgG4 against TGF-β1 currently being devel-
oped to treat scleroderma [245]. GC-1008 targets all
TGF-β isoforms and is in clinical trials for treatment of
melanoma and renal cell carcinoma [245]. Each of these
antibodies showed enough promise in early stage clinical
trials to warrant advancement to stage II/III clinical tri-
als, which are still currently underway [Figure 8].
Several small molecule inhibitors are also being devel-
oped. SD-093 and LY-580276, which are primarily inhib-
itors of SMAD2/3 activity, have been shown to inhibit
cell migration and invasion in cell culture models and
are proceeding to clinical trials [245].
The TGF-β/SMAD signaling pathway is much more
complex than that of JAK/STAT and is known to haveThe effects of EGF and TNF-alpha are mediate via the MEK-pathway.
d and studied for cancer treatment. However, the role of the
tegies may lend themselves equally well to this disease.
Aznaurova et al. Reproductive Biology and Endocrinology 2014, 12:50 Page 19 of 25
http://www.rbej.com/content/12/1/50dual roles in regulation of cell proliferation. The balance
of pro-proliferative and anti-proliferative effects must be
maintained in an effective therapy targeting this pathway.
Therefore, therapeutic development will be complex.
MEK/ERK Perhaps the most well studied pathway,
MEK/ERK signaling has several distinct advantages as
a therapeutic target. Firstly, most MEK inhibitors that
have been developed are very specific and do not inhibit
many different protein kinases [241]. Secondly, unlike
the TGF-β/SMAD pathway, targeting of MEK is highly
specific as ERK is the only known effector and the
downstream targets are fairly well defined [241]. Lastly,
MEK/ERK signaling represents a convergence of many
upstream signaling pathways that could be inhibited with a
single therapeutic.
Selumetinib is a small molecular inhibitor of MEK that
recently entered phase III clinical trials for treatment of
non-small cell lung cancer. Selumetinib has been shown
to be effective for inhibition of cell proliferation in sev-
eral tumor models, but does not affect the growth of
normal human cells [241]. It is thought that selumetinib
is cytostatic, meaning that it inhibits proliferation via cell
cycle arrest but does not induce apoptosis [Figure 9].
Selumetinib and other MEK/ERK inhibitors are being
primarily developed and studied for cancer treatment.
However, our analysis revealing the critical role of this
particular pathway in endometriosis suggests that these
therapeutic strategies may lend themselves equally well
to this disease.
Conclusions
Endometriosis is a common and painful condition affect-
ing women of reproductive age and the prevalence is
rapidly increasing internationally. However, the global
government funding for and the number of research
projects focusing on endometriosis have remained at the
relatively same level since 2008 and represent a minor
fraction of the female genitourinary cancers [178]. There
needs to be the increased international effort to under-
stand the etymology of endometriosis, explore preventa-
tive methods, and personalize treatment options.
While the underlying pathophysiology is still largely
unknown, many advancements have been made in un-
derstanding the progression of the disease. In recent
years, a great deal of research has focused on non-
invasive diagnostic tools, such as biomarkers, as well
as identification of potential therapeutic targets. The
current diagnostic tools are invasive and current therap-
ies primarily treat the symptoms of endometriosis. Opti-
mally, the advancement of genomic and proteomic data
will facilitate the development of non-invasive diagnostic
biomarkers as well as therapeutics that target the patho-
physiology of the disease and halt, or even reverse,progression. However, the amount of data generated by
these types of studies is vast and bioinformatics analysis,
such as we present here, will be critical to identification of
appropriate targets for further study.
Our network analysis identified the STAT proteins,
the SMAD transcription factors, and the MEK/ERK
pathways as central regulators for the pathophysio-
logical processes that drive development of endometriosis.
Therefore, these proteins and pathways have the potential
to yield clinically useful biomarkers and treatments for
endometriosis.
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